Biohaven Ltd.
opakalim
focal epilepsy
Countdown
177days
Phase 2 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 2 trial results for opakalim in focal epilepsy are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“initial topline results for the first study expected in 2H 2026.”